IMAGINE
VIRTUAL KOL EVENT
Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata
THURSDAY, OCTOBER 31, 2024 | 10:00 AM ET
AT INMAGENE
We are pioneering a new generation of therapies with best-in-class potential across a spectrum of immunological and inflammatory diseases. Leveraging external innovation and our proprietary QuadraTek® platform, we are developing differentiated treatments that have the potential to offer better outcomes to patients.
Our science
Our lead candidates have been engineered to address a broad spectrum of immune and inflammatory indications while optimizing safety, efficacy, and convenience.
Pipeline
We are developing a new generation of therapies for patients living with immunologic and inflammatory diseases.
Partnerships
Join our mission to deliver better therapies to patients in need.
News
Explore our most recent updates.